This study comprehensively demonstrated that suppression of IL-6 signaling sensitizes tumor cells to hormone therapies, suggestive of the potential therapeutic benefits of IL-6/STAT3 inhibition in luminal, hormone-dependent breast cancers. The gene discussed is STAT3; the disease is neoplasm.